Loma Linda University

Enrollment Information
Call us at: 909-558-1000

Faculty Directory
  
Jack Chen, PharmD
Associate Professor, Pharmacy Practice
School of Pharmacy
Associate Professor, Neurology
School of Medicine
Publications    Scholarly Journals--Published
  • Chen JJ, Ondo WG, Dashtipour K, Swope DM. Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature. Clin Ther 2012;34:1487-1504.

    ( 3/2012 )
  • Chen JJ. Drug-induced movement disorders. The Mental Health Clinician, January 2012 (Vol. 1, Iss. 7). Available at http://cpnp.org/resource/mhc/2012/01/drug-induced-movement-disorders. ( 1/2012 )
  • Chen JJ, Wilkinson JR. The monoamine type B inhibitor rasagiline in the treatment of Parkinson disease: Is tyramine a challenge? J Clin Pharmacol 2012;52:620-628. ( 0/2012 )
  • Chen JJ. Understanding available formulations of botulinum toxin agents. PowerPak CE. Dec 2011. Available at https://www.powerpak.com/course/preamble/107987. ( 12/2011 )
  • Chen JJ. Implications for managed care for improving outcomes in Parkinson’s disease: balancing aggressive treatment with appropriate care. Am J  Manag Care 2011;17(suppl):S322-S327 ( 0/2011 )
  • Chen JJ. Pharmacologic safety concerns in Parkinson’s disease: facts and insights. Int J Neurosci 2011;121(suppl2):45-52. ( 0/2011 )
  • Chen JJ. Parkinson''s disease: Health-related quality of life, economic cost, and implications of early treatment. Am J Manag Care 2010; 16:S87-S93. ( 0/2010 )
  • Chen JJ, Swope DM, Dashtipour K, Lyons KE. Transdermal rotigotine: a clinically innovative dopamine receptor agonist for the management of Parkinson''s disease. Pharmacotherapy 2009;29:1452-1467. ( 0/2009 )
  • Chen JJ, Lew MF, Siderowf A. Treatment strategies and quality of care indicators for patients with Parkinson''s disease. J Manag Care Pharm 2009;15(suppl 3) :S2-S21. ( 0/2009 )
  • Chen JJ. Telcagepant: the next blockbuster migraine treatment? APhA DrugInfoLine 2009;10(2):5. ( 0/2009 )
  • Chen JJ. Modafinil''s effects on dopamine APhA DrugInfoLine 2009;10(5):5-6. ( 0/2009 )
  • Chen JJ, Lew MF, Siderowf A. Treatment strategies and quality of care indicators for patients with Parkinson''''s disease. J Manag Care Pharm 2009;15(suppl 3):S2-S21. ( 0/2009 )
  • Chen, JJ. Parkinsons Disease Expert Column: Pharmacoeconomics of Parkinsons disease: focus on monoamine oxidase type B inhibitors. Medscape Neurology & Neurosurgery. July 31, 2008. ( 7/2008 ) Link...
  • Chen JJ, Trombetta DP, Fernandez HH. Palliative Management of Parkinson Disease: Focus on Nonmotor, Distressing Symptoms. Journal of Pharmacy Practice 2008;21:262-272. ( 6/2008 )
  • Waters CH, Chen JJ. Pharmacologic Options for Treatment of Levodopa-Associated “wearing off.” Journal of Pharmacy Practice 2008;21:254-261. ( 6/2008 )
  • Chen JJ, Pahwa R. Pharmacologic management of Parkinson disease: choice of initial therapy in early disease. Journal of Pharmacy Practice 2008;21:244-253. ( 6/2008 )
  • Swope DM, Chen JJ, Sadiqua N. Adult onset focal truncal dystonia and improvement with botulinum toxin A. Mov Disord 2008;23(suppl 1):S177. ( 5/2008 )
  • Jacob S, Chen JJ. Restless legs syndrome in the elderly. Long-Term Care Interface 2008;March/April:38-43. ( 4/2008 )
  • Dashtipour K, Chen JJ, Lew MF. Rasagiline for the management of Parkinson’s disease. Therapy 2008;5:203-214. ( 4/2008 )
  • Weart CW, Chen JJ. Biogen Idec, Elan warn of significant liver damage with natalizumab. APhA DrugInfoLine 2008;9(3):1-2. ( 0/2008 )
  • Chen JJ. Botulinum toxin type B as effective as type A for toxin-naive patients with cervical dystonia. APhA DrugInfoLine 2008;9(7/8):4-5. ( 0/2008 )
  • Chen JJ, Uffindell SH. Neuroprotective therapy for stroke remains an unmet need. APhA DrugInfoLine 2008;9(11/12):2-4. ( 0/2008 )
  • Swope DM, Chen JJ, Sadiqua N. Adult onset focal truncal dystonia and improvement with botulinum toxin A. Mov Disord 2008;23(suppl 1):S177. ( 0/2008 )
  • Chen JJ, Panisset M, Schwid S, Ondo W, Fitzer-Attas C. Safety of concomitant therapy with rasagiline and antidepressants in Parkinson''s disease. J Amer Pharm Assoc 2008;48:233. ( 0/2008 )
  • Chen JJ, Swope DM. Pharmacotherapy for Parkinson’s disease. Pharmacotherapy 2007;27 (12 Pt 2):161S-173S. ( 12/2007 )
  • Fernandez HH, Chen JJ. Monoamine-B inhibition in the treatment of Parkinson’s disease. Pharmacotherapy 2007;27 (12 Pt 2):174S-185S. ( 12/2007 )
  • Claxton KL, Chen JJ, Swope D. Drug-induced movement disorders. Journal of Pharmacy Practice 2007;20:415-429. ( 11/2007 )
  • Chen JJ, Swope D. Essential tremor. Journal of Pharmacy Practice 2007;20:458-468. ( 11/2007 )
  • Chen JJ. Drug-induced movement disorders: a primer. U.S. Pharmacist 2007;32(11):HS16-HS32. ( 11/2007 )
  • Chen JJ. Optimizing use of a dopamine agonist in Parkinson’s disease. Pharmacy Times 2007;73(7):111-21. ( 8/2007 )
  • Chen JJ. Rasagiline is effective and well tolerated in Parkinson’s disease patients with levodopa-related motor fluctuations receiving serotonin reuptake inhibitors. Pharmacotherapy 2007;27:e18. ( 8/2007 )
  • Chen JJ. Rasagiline is effective and well tolerated as adjunct therapy in Parkinson’s disease patients receiving levodopa and entacapone. Pharmacotherapy 2007;27:e18. ( 8/2007 )
  • Obering C, Chen JJ. Rasagiline adjunct therapy produces marked levels of response across all Parkinson’s disease severities: pooled data analysis from the PRESTO and LARGO studies. Pharmacotherapy 2007;27:1471. ( 8/2007 )
  • Panisset M, Schwid S, Ondo W, Fitzer-Attas C, Chen JJ. Safety of concomitant therapy with rasagiline and antidepressants in Parkinson’s disease. Mov Disord 2007;223(suppl 16):S104-S105. ( 6/2007 )
  • Lee KC, Chen JJ. Transdermal selegiline for the treatment of major depressive disorder. Neuropsychiatric Disease and Treatment 2007;3:527-537. ( 6/2007 )
  • Chen JJ, Swope DM, Dashtipour K. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson’s disease. Clin Ther 2007;29:1825-49. ( 5/2007 )
  • Chen JJ, Fernandez HH. Community and long-term care management of Parkinson’s disease in the elderly: focus on MAO-B inhibitors. Drugs Aging 2007;24:663-680. ( 5/2007 )
  • Fernandez HH, Chen JJ. Monoamine oxidase inhibitors: current and emerging agents for Parkinson disease. Clin Neuropharmacol 2007;30:150-168. ( 5/2007 )
  • Chen JJ. Pharmacology and pharmacokinetics of rasagiline: A selective, irreversible, second-generation MAO-B inhibitor. Formulary 2006;41(Suppl 10):18–24. ( 11/2006 )
  • Obering CD, Chen JJ, Swope DM. Update on rapid treatment of hypomobility (“off”) episodes in patients with Parkinson’s disease. Pharmacotherapy 2006;26:840-52. ( 10/2006 )
  • Chen JJ, Lee KC. Nonparkinsonism movement disorders in the elderly. Consult Pharm 2006;21:58-71. ( 6/2006 )
  • Swope DM, Chen JJ. Effectiveness and tolerability of pregabalin for dystonia and other hyperkinetic movement disorders: An open-label exploratory study. Mov Disord 2006;21(suppl 15):S385-S386. ( 6/2006 )
  • Chen JJ, Langston JW, Jankovic J, Chang FL. Transdermal rotigotine: evaluation of efficacy and continuous drug delivery in Parkinson’s disease. Pharmacotherapy 2006;26:e78. ( 5/2006 )
  • Chen JJ, Berchou RC, Obering C. Rasagiline does not promote a tyramine pressor response in levodopa-treated patients with Parkinson’s disease. Pharmacotherapy 2006;26:e77-78. ( 5/2006 )
  • Chen JJ, Berchou RC, Obering C. Lack of rasagiline-tyramine interaction in levodopa-naive patients with Parkinson’s disease. Pharmacotherapy 2006;26:e78. ( 5/2006 )
  • Berchou RC, Chen JJ, Obering C. Rasagiline, a second-generation, selective, irreversible MAO-B inhibitor is effective in patients with early Parkinson’s disease (The TEMPO Study). Pharmacotherapy 2006;26:e78. ( 5/2006 )
  • Chen JJ, Berchou RC, Obering C. Rasagiline mesylate reduces leovodopa-related motor fluctuations in Parkinson’s disease (PD) patients: The Parkinson’s Rasagiline Efficacy and Safety in the treatment of “Off” (PRESTO). Consult Pharm 2006;21:830. ( 4/2006 )
  • Shankar GS, Lee KC, Chen JJ. "Metabolic and endocrinologic adverse effects of atypical antipsychotic agents.." California Pharmacist 54. (2006): 12-17. ( 1/2006 )
  • Obering CD, Chen JJ, Swope DM. . "Update on rapid treatment of hypomobility (?off?) episodes in patients with Parkinson?s disease.." Pharmacotherapy 26. (2006): 840-852. ( 1/2006 )
  • Chen JJ, Lee KC. "Nonparkinsonism movement disorders in the elderly. ." Consult Pharm 21. (2006): 58-71. ( 1/2006 )
  • Chen JJ, Lee KC. . "Recognition and management of drug-induced movement disorders. ." California Pharmacist 53. (2006): 18-24. ( 1/2006 )
  • Chen JJ, Berchou RC. Low incidence of cognitive and behavioral adverse events in rasagiline-treated patients with early to advanced Parkinson’s disease. Pharmacotherapy 2005;25:1466. ( 11/2005 )
  • Chen JJ, Berchou RC. Rasagiline is effective as monotherapy in patients with early Parkinson’s disease and as adjunctive therapy in moderate to advanced PD. Pharmacotherapy 2005; 25:1466-67. ( 10/2005 )
  • Berchou RC, Chen JJ. Rasagiline provides significant management of motor symptoms in early and moderate-to-advanced Parkinson’s disease. Pharmacotherapy 2005; 25:1467. ( 10/2005 )
  • Chen JJ, Swope DM, Gascon RS. Zonisamide for the treatment of essential tremor: a case study. Pharmacotherapy 2005;25:1466. ( 10/2005 )
  • Chen JJ, Swope DM,Nist L. Botulinum toxin for cervical dystonia in myasthenia gravis: a case study. Pharmacotherapy 2005;25:1466. ( 10/2005 )
  • Chen JJ, Obering C.. "Apomorphine in the management of motor fluctuations associated with Parkinson?s disease. ." Clin Ther 27. (2005): 1710-1724. ( 10/2005 )
  • Chen JJ. "Management of wearing off in Parkinson?s disease. ." Consult Pharm 20. (2005): s15-s21. ( 10/2005 )
  • Chen JJ. "The role of the consultant pharmacist in Parkinson?s disease. ." Consult Pharm 20. (2005): s22-s25. ( 10/2005 )
  • Chen JJ, Swope DM. "Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson?s disease. ." J Clin Pharmacol 45. (2005): 878-894. ( 10/2005 )
  • Chen JJ, Swope DM.. "Case of Complex Movement Disorder Induced by Fluoxetine With Management of Dystonia by Botulinum Toxin Type A.." J Clin Psych 66. (2005): 267-268. ( 9/2005 )
  • Chang P, Okamoto M, Chen JJ, Frame DG.. "Cost-effectiveness analysis of ondansetron and prochlorperazine for the prevention of postoperative nausea and vomiting. ." J Manag Care Pharm 11. (2005): 317-321. ( 8/2005 )
  • Chen JJ, Swope DM. A Case of Complex Movement Disorder Induced by Fluoxetine With Management of Dystonia by Botulinum Toxin Type A. J Clin Psychiatry 2005;66:267-268. ( 8/2005 )
  • Chen J. Pharmacuetica philatelica in recognition of American pharmacy. J Am Pharm Assoc 2005;45:291. ( 8/2005 )
  Books and Chapters
  • Chen JJ. Parkinson Disease. In: Richardson M, Chant C, Chessman KH, et al, eds. Pharmacotherapy Self-Assessment Program, 7th ed. Neurology and Psychiatry. Lenexa, KS: American College of Clinical Pharmacy, 2012:111-32.

    ( 3/2012 )
  • Chen JJ. Parkinson’s Disease. In: Ginsberg DB, Eiland LS (eds). PharmPrep ASHP’s NAPLEX Review, CD-ROM with book. Bethesda: American Society of Health-System Pharmacists, 4th edition, 2011:119-121.

    ( 8/2011 )
  • Chen JJ, Nelson MV, Swope DM. Parkinson’s Disease. In: DiPiro JT, Talbert RL, Yee GC, et al (eds). Pharmacotherapy: A Pathophysiologic Approach. New York: McGraw Hill, 8th edition, 2011:1033-1044.

    ( 8/2011 )
  • Chen JJ. Monoamine Oxidase Type B Inhibitors. In: Komoliti K, Verhagen L (eds). The Encyclopedia of Movement Disorders. New York: Elsevier, 1st edition, 2010:190-193. ( 0/2010 )
  • Chen JJ and Swope DM. Movement Disorders. In: Tisdale J, Miller D (eds). Drug-Induced Diseases: Prevention, Detection, and Management.  Bethesda: American Society of Health-System Pharmacists, 2nd edition, 2010:211-235. ( 0/2010 )
  • Chen JJ, Nelson MV, Swope DM. Parkinson’s Disease. In: DiPiro JT, Talbert RL, Yee GC, et al (eds). Pharmacotherapy: A Pathophysiologic Approach. New York: McGraw Hill, 7th edition, 2008:977-988. ( 6/2008 )
  • Chen JJ. Nelson MV, Swope DM. Parkinson''s Disease. In: DiPiro JT, Talbert RL, Yee GC, et al (eds). Pharmacotherapy: A Pathophysiologic Approach. New York: McGraw Hill, 7th edition, 2008:977-988. ( 0/2008 )
  • Chen JJ. Management of Depression and Anxiety. In: Pahwa R, Lyons KM (eds). Handbook of Parkinson’s Disease. New York: Informa Healthcare, 4th edition, 2007:133-153. ( 8/2007 )
  • Chen JJ and Shimomura SK. Parkinson’s Disease. In: Ginsberg D (ed). ASHP’s PharmPrep Interactive Case-based Board Review, CD-ROM with book. Bethesda: American Society of Health-System Pharmacists, 3rd edition, 2007. ( 4/2007 )
  • Shapiro K and Chen JJ.. Dementia. Natural Products: A Case-Based Approach for Health Care Professionals. : American Pharmacists Association, 2006. 15 - 24 ( 1/2006 )
  • Shapiro K and Chen JJ.. Migraine. Natural Products: A Case-Based Approach for Health Care Professionals. : American Pharmacists Association, 2006. 25 - 36 ( 1/2006 )
  • Chen JJ and Shimomura SK. . Parkinsons Disease. ASHPs PharmPrep Case-based Board Review, CD-ROM with book: American Society of Health-System Pharmacists, 2006. ( 1/2006 )
  • Chen JJ, Shimomura SK. Parkinsonism. ). The Textbook of Therapeutics: Drug and Disease Management. : Williams & Wilkins, 2006. 1646 - 1670 ( 1/2006 )
  • Chen JJ, Swope DM. Movement Disorders. Drug-Induced Diseases: Prevention, Detection, and Management.: American Society of Health-System Pharmacists, 2005. 137 - 157 ( 7/2005 )
  • Chen JJ. Outline for the management of Parkinson?s disease (algorithm). . ). A Guide to Clinical Decision-Making: The PSAP Algorithms: American College of Clinical Pharmacy, 2005. 51 - 51 ( 7/2005 )
  • Chen JJ. Outline for the management of essential tremor (algorithm). . A Guide to Clinical Decision-Making: The PSAP Algorithms: American College of Clinical Pharmacy, 2005. 52 - 52 ( 7/2005 )
  • Shankar G, Lee K, Chen J. . Management of metabolic disturbances associated with antipsychotic drugs (algorithm). . : American College of Clinical Pharmacy, 2005. 65 - 65 ( 7/2005 )
  • Shankar G, Lee K, Chen J. Management of sexual dysfunction due to antidepressants (algorithm). . A Guide to Clinical Decision-Making: The PSAP Algorithms: American College of Clinical Pharmacy, 2005. 66 - 66 ( 7/2005 )
  • Chen JJ, Swope DM. Movement Disorders. Drug-Induced Diseases: Prevention, Detection, and Management.: American Society of Health-System Pharmacists, 2005. 137 - 157 ( 1/2005 )
  • Chen JJ. Management of Depression and Anxiety.. Handbook of Parkinsons Disease. : Taylor & Francis Group, LLC, . (*)
  Non-Scholarly Journals
  • Chen JJ. Student Saints. Christianity & Pharmacy 2012;15(1):22-23.

    ( 10/2012 )
  • Chen JJ. Mere Pharmacists (A prayer poem). Christianity & Pharmacy 2011;14(1):21-22.

    ( 10/2011 )
  • Becker T, Chen JJ, Lew M. Azilect. New Product Bulletin. American Pharmacists Association; 2006. ( 8/2006 )
  • Dong BJ, Chen JJ. "Neuropathies common with stavudine, didanosine." APhA DrugInfoLine 01 01 2006: 2 - 3 ( 1/2006 )
  • Chen JJ, Swope DM"Levodopa dosing: a balancing act (Part II). ." Schwarz Pharma Parkinson Report 01 01 2006: 11 - 12 ( 1/2006 )
  • Chen JJ"Antiepileptic drugs can affect bone mineral density. ." APhA DrugInfoLine 01 01 2006: 2 - 3 ( 1/2006 )
  • Chen JJ"New pain guidelines emphasize quality of care.." APhA DrugInfoLine 01 12 2005: 6 - 6 ( 12/2005 )
  • Chen JJ, Swope DM"Levodopa dosing: a balancing act. ." Schwarz Pharma Parkinson Report 01 11 2005: 8 - 10 ( 11/2005 )
  • Chen JJ"Biogen Idec offers strategy for resuming use of natalizumab.." APhA DrugInfoLine 01 11 2005: 1 - 2 ( 11/2005 )
  • Chen JJ"Avoid valproate in fertile women." APhA DrugInfoLine 01 09 2005: 6 - 7 ( 9/2005 )
  • Chen JJ"PD: levodopa, rivastigmine under study. ." APhA DrugInfoLine 01 07 2005: 2 - 4 ( 7/2005 )